An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
At present, surgery, radiotherapy and chemotherapy are the main treatment methods for
patients with advanced gastrointestinal cancer. Although targeted therapy has significantly
improved the prognosis of patients, the mortality of patients has not been significantly
reduced, so new treatment methods are urgently needed. In recent years, immunotherapy has
become a new hotspot in tumor therapy. Compared with traditional treatment, immune checkpoint
inhibitors (ICIS) have shown long-term good efficacy and tolerance in clinical trials.
However, single drug ICIS has reached a bottleneck for advanced gastrointestinal cancer, with
low response rate and poor PFS and OS. With the results of REGONIVO showing good efficacy,
the treatment mode of immune combined with small molecule anti angiogenesis drugs has sprung
up. The purpose of this study was to analyze the efficacy and safety of in Camrelizumab
combination with Apatinib mesylate in advanced gastrointestinal cancer.